Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

S. Glück

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)86-87
Number of pages2
JournalBreast Diseases
Volume19
Issue number1
DOIs
StatePublished - Apr 1 2008

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this